August 6, 2025Frontiers in PharmacologyOpen Access

Exploring dupilumab for asthma: from mechanistic insights to clinical outcomes, safety, and cost-effectiveness

View Full Paper

Ask AI

Bookmark

Dupilumab significantly reduces asthma exacerbation rates and improves FEV1 in moderate-to-severe asthma patients.
The drug showcases nonlinear pharmacokinetics with 61% bioavailability and supports biweekly SC administration.
Safety profile indicates mild adverse events are common, with nonclinical studies showing no systemic toxicity.
Economically, dupilumab is cost-effective in several countries but faces challenges in high-cost regions like the US.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Review highlights dupilumab's clinical efficacy and cost-effectiveness in asthma treatment, suggesting benefits for T2-high and selected T2-low phenotypes.

Cite This Study

Ameer et al. (2025) studied this question.

synapsesocial.com/papers/689522189f4f1c896c429de2 https://doi.org/10.3389/fphar.2025.1631321

View Full Paper

Ask AI

Bookmark

Implication

Review highlights dupilumab's clinical efficacy and cost-effectiveness in asthma treatment, suggesting benefits for T2-high and selected T2-low phenotypes.

Exploring dupilumab for asthma: from mechanistic insights to clinical outcomes, safety, and cost-effectiveness

Key Points

Discussion

Implication

Cite This Study

Exploring dupilumab for asthma: from mechanistic insights to clinical outcomes, safety, and cost-effectiveness

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading